David Mitchell
General Counsel chez VERASTEM, INC.
Profil
David C.
Mitchell currently works at Verastem, Inc., as Senior Vice President & Head-Regulatory Affairs from 2023.
Mr. Mitchell also formerly worked at Biogen, Inc., as Director-Regulatory Affairs from 2000 to 2004, CancerVax Corp., as Senior Director-Regulatory Affairs & Quality, Reata Pharmaceuticals, Inc., as Director-Regulatory Affairs & Quality Assurance, The Upjohn Co., as Principal, Novalar Pharmaceuticals, Inc., as VP-Regulatory Affairs & Quality Assurance, Spyre Therapeutics, Inc., as Vice President-Regulatory Affairs & Quality, Aquinox Pharmaceuticals, Inc., as VP-Global Regulatory Affairs & Quality Assurance from 2014 to 2017, Actelion Pharmaceuticals US, Inc., as Principal, and Sumitovant Biopharma, Inc., as Senior Vice President & Head-Regulatory Affairs.
Mr. Mitchell received his graduate degree from The Johns Hopkins University and undergraduate degree from Mississippi College.
Postes actifs de David Mitchell
| Sociétés | Poste | Début |
|---|---|---|
| VERASTEM, INC. | General Counsel | 26/10/2023 |
Anciens postes connus de David Mitchell
| Sociétés | Poste | Fin |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | General Counsel | 01/03/2019 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | General Counsel | 15/03/2017 |
| BIOGEN INC. | General Counsel | 01/01/2004 |
Sumitovant Biopharma, Inc.
 Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | General Counsel | - |
Novalar Pharmaceuticals, Inc.
 Novalar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Novalar Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on dental products. The company's OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. The company was founded in 2000 and is headquartered in San Diego, CA. | General Counsel | - |
Formation de David Mitchell
| The Johns Hopkins University | Graduate Degree |
| Mississippi College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
| The Upjohn Co. | Health Technology |
| CancerVax Corp. | Commercial Services |
Novalar Pharmaceuticals, Inc.
Novalar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Novalar Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on dental products. The company's OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. The company was founded in 2000 and is headquartered in San Diego, CA. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Actelion Pharmaceuticals US, Inc.
 Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a private company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | Health Technology |
Sumitovant Biopharma, Inc.
Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Health Technology |
